Pharmaceutical Executive
Washington, DC-The run on Cipro following October's anthrax scare was a bonanza for pharmacy websites, but it stirred the wrath of both FDA and the medical establishment. In response to escalating ciprofloxacin promotion over the internet, FDA sent cyber letters to 11 websites for offering US consumers products that may not be approved for sale in the United States, warning that US Customs might detain shipments. The agency also took more stringent action against five previously warned foreign vendors.
Washington, DC-The run on Cipro following October's anthrax scare was a bonanza for pharmacy websites, but it stirred the wrath of both FDA and the medical establishment. In response to escalating ciprofloxacin promotion over the internet, FDA sent cyber letters to 11 websites for offering US consumers products that may not be approved for sale in the United States, warning that US Customs might detain shipments. The agency also took more stringent action against five previously warned foreign vendors.
Pharmacists also were quick to alert the public to the risk of purchasing antibiotics online, because the products could be counterfeit, contaminated, expired, or ineffective. Pharmacists generally oppose internet and mail-order sales of medicines, especially from overseas vendors.
And those operators' assertions that they will fill a prescription only after an online "consultation" with a doctor have antagonized the medical community. The North Carolina Medical Board brought charges against a physician for writing Cipro prescriptions with only a "virtual" check-up, performed through VirtualMedicalGroup, which is linked to the state's MedicalWeb.com. Although the North Carolina medical board stated that online prescribing is unprofessional and "inappropriate," it is not illegal in most states. VirtualMedicalGroup says it obtains Cipro from a US wholesaler, which may keep it out of trouble with FDA.
Before the Cipro shortage, online pharmacy operations had moved out of the limelight, according to Anne Maher, formerly with the Federal Trade Commission. Last year's dotcom crash and the demise of some big pharmacy websites further depleted the relatively low number of consumers using those services, and a regulatory crackdown by FTC and FDA also hurt the budding field. FTC continues to watch online pharmacy activities, but it probably spends more energy keeping track of how marketers provide product information to consumers through their websites.
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.